A Phase 3 interventional study of Double-blind adalimumab and Double-blind Placebo in Rheumatoid Arthritis, sponsored by Abbott. Completed at 88 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2012-08-07.
Sponsored by Abbott · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 87 studies testing adalimumab in Arthritis, Rheumatoid — 4 open to participants now, 6 under way, 2 of them phase 3. Adalimumab · Arthritis, Rheumatoid.
Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, this one is the 28th largest by enrollment, is one of 4 that started in 2009, is one of 36 in phase 3, and was the 33rd registered.
3,336 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →4 of the 87 studies testing adalimumab in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Medical Center Groningen · Sites in Netherlands
Ages 18+
Qilu Hospital of Shandong University · Sites in China
Ages 18–80
University of Nebraska · Sites in United States
Ages 19+
By country, each count listing its studies:
Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
87 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 12 · Phase 3 39 · Phase 4 33
First in 2000; this study’s year is marked. 4 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 334 is above the median of 96 across 2,223 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 160 across the 87 interventional studies. Of the 73 that completed or were terminated, 43 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
53 of 87 have an industry lead sponsor. The 10 most frequent:
Abbott is the lead sponsor of 361 studies on the registry; 1 is open to participants now.
33 studies in Arthritis, Rheumatoid by Abbott: none open now, none under way, none of them phase 3. Of 30 finished, 19 (63%) have results posted.
Among the 33 studies in Arthritis, Rheumatoid by Abbott, this one is the 10th largest by enrollment of the 22 interventional ones that give a count, is the only one that started in 2009, is one of 14 in phase 3, and was the 25th registered.
Abbott’s Arthritis, Rheumatoid studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Abbott’s 33 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the potential of adalimumab to inhibit radiographic progression in joint destruction compared with placebo in adult Japanese subjects with recent onset of rheumatoid arthritis.
This was a Phase 3 multicenter, randomized, double-blind, parallel group, placebo-controlled study designed to evaluate the inhibition of radiographic progression by adalimumab compared with placebo in adult Japanese patients with early rheumatoid arthritis (RA) who had not been previously treated with methotrexate (MTX). Eligible participants were randomized 1:1 to receive either a subcutaneous injection of adalimumab 40 mg or matching placebo every other week (eow) during the 26-week double-blind phase. All participants also received 6 mg to 8 mg MTX weekly as basal treatment for their disease. Participants who experienced an increase in disease activity (more than 20% increase in tender joint count and swollen joint count) at Week 12, 16, or 20 compared with Baseline after having increased MTX dose to 8 mg per week for at least 4 weeks were discontinued from the double-blind phase and were eligible to receive open-label adalimumab 40 mg eow as rescue treatment. Participants who completed the 26 weeks of treatment (either double-blind study drug [adalimumab or placebo] treatment or open-label adalimumab treatment) were eligible to enter the 26-week open-label phase in which they received adalimumab 40 mg eow. Efficacy and safety assessments were performed at Baseline and at designated study visits.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received double-blind placebo administered subcutaneously (SC) every other week (eow) for up to 26 weeks. Participants also received concomitant methotrexate 6 to 8 mg administered orally weekly.
Drug: Double-blind Placebo
Participants received double-blind adalimumab 40 mg administered subcutaneously (SC) every other week (eow) for up to 26 weeks. Participants also received concomitant methotrexate 6 to 8 mg administered orally weekly.
Biological: Double-blind adalimumab
Participants received double-blind adalimumab administered subcutaneously (SC) every other week (eow) for 26 weeks followed by open-label adalimumab 40 mg SC eow for up to 26 weeks. Participants also received concomitant methotrexate 6 to 8 mg administered orally weekly.
Biological: Double-blind adalimumab · Biological: Open-label Adalimumab
Participants received double-blind placebo administered subcutaneously (SC) every other week (eow) for 26 weeks followed by open-label adalimumab 40 mg SC eow for up to 26 weeks. Participants received concomitant methotrexate 6 to 8 mg administered orally weekly.
Drug: Double-blind Placebo · Biological: Open-label Adalimumab
Participants received double-blind adalimumab 40 mg administered subcutaneously (SC) every other week (eow) and then open-label adalimumab 40 mg SC eow as rescue treatment (as eligible at Week 12 or after) to complete 26 weeks, followed by open-label adalimumab 40 mg SC eow for up to 26 weeks. Participants received concomitant methotrexate 6 to 8 mg administered orally weekly.
Biological: Double-blind adalimumab · Biological: Open-label Adalimumab · Biological: Open-labelAdalimumabRescue
Participants received double-blind placebo administered subcutaneously (SC) every other week (eow) and then open-label adalimumab 40 mg SC eow as rescue treatment (as eligible at Week 12 or after) to complete 26 weeks, followed by open-label adalimumab 40 mg SC eow for up to 26 weeks. Participants received concomitant methotrexate 6 to 8 mg administered orally weekly.
Drug: Double-blind Placebo · Biological: Open-label Adalimumab · Biological: Open-labelAdalimumabRescue
Double-blind adalimumab 40 mg administered subcutaneously (SC) every other week (eow)
Also known as: ABT-D2E7, adalimumab, Humira
Double-blind adalimumab-matching placebo administered subcutaneously (SC)every other week (eow)
Also known as: Placebo
Open-label adalimumab 40 mg administered subcutaneously (SC) every other week (eow) after completion of the first 26 weeks in the study
Also known as: ABT-D2E7, adalimumab, Humira
Open-label adalimumab 40 mg administered subcutaneously (SC) every other week (eow) as rescue treatment to complete the first 26 weeks in the study- dependent on participant eligibility (increase in disease activity), applies to Weeks 12 to 26
Also known as: ABT-D2E7, adalimumab, Humira
Change From Baseline in Modified Total Sharp X-Ray Score at Week 26
Modified Total Sharp Score (mTSS) is a measure of joint health, used in evaluation of inhibition of radiographic progression of disease. Digitized X-rays of hands and feet were obtained then scored in a blinded manner: for erosions (0 \[no damage\] to 5 \[complete collapse or total destruction of joint\]) and for joint space narrowing (0 \[no damage\] to 4 \[complete luxation of joint\]). Scores were added, giving total mTSS (0 \[normal\] to 380 \[maximal disease\]). Large positive change in mTSS indicates disease progression; small positive/no change indicates slowing/halting of disease progression.
Time frame: Baseline, Week 26
Number of Participants Meeting ACR20 Response Criteria at Week 26 (ACR: American College of Rheumatology)
Patients were ACR20 responders if they had: \>= 20% improvement in both tender joint count (68 joints) and in swollen joint count (66 joints) plus \>=20% improvement in at least 3 of the 5 remaining ACR core measures: patient's assessment of pain; patient's global assessment of disease activity; physician's global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant C-reactive protein. Patients who discontinued or switched to open-label adalimumab prior to Week 26 were considered non-responders.
Time frame: Week 26
Number of Participants Meeting ACR50 Response Criteria at Week 26 (ACR: American College of Rheumatology)
Patients were ACR50 responders if they had: \>= 50% improvement in both tender joint count (68 joints) and in swollen joint count (66 joints) plus \>=50% improvement in at least 3 of the 5 remaining ACR core measures: patient's assessment of pain; patient's global assessment of disease activity; physician's global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant C-reactive protein. Patients who discontinued or switched to open-label adalimumab prior to Week 26 were considered non-responders.
Time frame: Week 26
Number of Participants Meeting ACR70 Response Criteria at Week 26 (ACR: American College of Rheumatology)
Patients were ACR70 responders if they had: \>= 70% improvement in both tender joint count (68 joints) and in swollen joint count (66 joints) plus \>=70% improvement in at least 3 of the 5 remaining ACR core measures: patient's assessment of pain; patient's global assessment of disease activity; physician's global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant C-reactive protein. Patients who discontinued or switched to open-label adalimumab prior to Week 26 were considered non-responders.
Time frame: Week 26
Change From Baseline in Disease Activity Score (DAS28[ESR]) at Week 26
Disease Activity Score (DAS28) is a combined index used to measure disease activity in patients with rheumatoid arthritis. Calculation of the DAS28 score used the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity, and the erythrocyte sedimentation rate. DAS28(ESR) scores range from 0 (no disease activity) to 9 (maximal disease activity); decrease is indicative of improvement in disease activity.
Time frame: Baseline, Week 26
Number of Participants Achieving Clinical Remission, Defined by Disease Activity Score (DAS28[ESR]) <2.6, at Week 26
Disease Activity Score (DAS28) is a combined index used to measure disease activity in patients with rheumatoid arthritis. Calculation of the DAS28 score used the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity, and the erythrocyte sedimentation rate. DAS28(ESR) scores range from 0 (no disease activity) to 9 (maximal disease activity); decrease is indicative of improvement in disease activity. DAS28(ESR) score \<2.6 was defined as clinical remission of disease.
Time frame: Week 26
Number of Participants Who Reported Any Adverse Event (Serious or Non-serious) on Double-blind Study Drug Through Week 26
Adverse events were collected at designated study visits for all participants who were randomized and received at least 1 dose of study drug. The number of participants who experienced any adverse event (serious or non-serious) while receiving double-blind study drug is summarized. See the Reported Adverse Event section for details.
Time frame: Through Week 26
Change From Baseline in Modified Total Sharp X-Ray Score at Week 52
Modified Total Sharp Score (mTSS) is a measure of joint health, used in evaluation of inhibition of radiographic progression of disease. Digitized X-rays of hands and feet were obtained then scored in a blinded manner: for erosions (0 \[no damage\] to 5 \[complete collapse or total destruction of joint\]) and for joint space narrowing (0 \[no damage\] to 4 \[complete luxation of joint\]). Scores were added, giving total mTSS score (0 \[normal\] to 380 \[maximal disease\]). Large positive change in mTSS indicates diseae progression; small positive/no change indicates slowing/halting of disease progression.
Time frame: Baseline, Week 52
Number of Participants Meeting ACR20 Response Criteria at Week 52 (ACR: American College of Rheumatology)
Patients were ACR20 responders if they had: \>=20% improvement in both tender joint count (68 joints) and in swollen joint count (66 joints) plus \>=20% improvement in at least 3 of the 5 remaining ACR core measures: patient's assessment of pain; patient's global assessment of disease activity; physician's global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire (HAQ); and acute phase reactant C-reactive protein.
Time frame: Week 52
Number of Participants Meeting ACR50 Response Criteria at Week 52 (ACR: American College of Rheumatology)
Patients were ACR50 responders if they had: \>=50% improvement in both tender joint count (68 joints) and in swollen joint count (66 joints) plus \>=50% improvement in at least 3 of the 5 remaining ACR core measures: patient's assessment of pain; patient's global assessment of disease activity; physician's global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire (HAQ); and acute phase reactant C-reactive protein.
Time frame: Week 52
Number of Participants Meeting ACR70 Response Criteria at Week 52 (ACR: American College of Rheumatology)
Patients were ACR70 responders if they had: \>=70% improvement in both tender joint count (68 joints) and in swollen joint count (66 joints) plus \>=70% improvement in at least 3 of the 5 remaining ACR core measures: patient's assessment of pain; patient's global assessment of disease activity; physician's global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire (HAQ); and acute phase reactant C-reactive protein.
Time frame: Week 52
Change From Baseline in Disease Activity Score (DAS28[ESR]) at Week 52
Disease Activity Score (DAS28) is a combined index used to measure disease activity in patients with rheumatoid arthritis. Calculation of the DAS28 score used the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity, and the erythrocyte sedimentation rate. DAS28(ESR) scores range from 0 (no disease activity) to 9 (maximal disease activity); decrease is indicative of improvement in disease activity.
Time frame: Baseline, Week 52
Number of Participants Achieving Clinical Remission, Defined by Disease Activity Score (DAS28[ESR]) <2.6, at Week 52
Disease Activity Score (DAS28) is a combined index used to measure disease activity in patients with rheumatoid arthritis. Calculation of the DAS28 score used the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity, and the erythrocyte sedimentation rate. DAS28(ESR) scores range from 0 (no disease activity) to 9 (maximal disease activity); decrease is indicative of improvement in disease activity. DAS28(ESR) score \<2.6 was defined as clinical remission of disease.
Time frame: Week 52
Number of Participants Who Reported Any Adverse Event (Serious or Non-serious) While Receiving Adalimumab Through Week 52
Adverse events were collected at designated study visits for all participants who were randomized and received at least 1 dose of adalimumab. The number of participants who experienced any adverse event (serious or non-serious) while receiving any adalimumab during the study (double-blind adalimumab and/or open-label) is summarized. See the Reported Adverse Event section for details.
Time frame: Through Week 52
| Milestone | DB Adalimumab | DB Placebo | DB Adalimumab/OL Adalimumab | DB Placebo/OL Adalimumab | DB Adalimumab/RE OL Adalimumab | DB Placebo/RE OL Adalimumab |
|---|---|---|---|---|---|---|
| Started | 171 | 163 | 0 | 0 | 0 | 0 |
| Completed | 155 | 151 | 0 | 0 | 0 | 0 |
| Not completed | 16 | 12 | 0 | 0 | 0 | 0 |
| Milestone | DB Adalimumab | DB Placebo | DB Adalimumab/OL Adalimumab | DB Placebo/OL Adalimumab | DB Adalimumab/RE OL Adalimumab | DB Placebo/RE OL Adalimumab |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 145 | 127 | 10 | 24 |
| Completed | 0 | 0 | 132 | 120 | 5 | 21 |
| Not completed | 0 | 0 | 13 | 7 | 5 | 3 |
Modified Total Sharp Score (mTSS) is a measure of joint health, used in evaluation of inhibition of radiographic progression of disease. Digitized X-rays of hands and feet were obtained then scored in a blinded manner: for erosions (0 \[no damage\] to 5 \[complete collapse or total destruction of joint\]) and for joint space narrowing (0 \[no damage\] to 4 \[complete luxation of joint\]). Scores were added, giving total mTSS (0 \[normal\] to 380 \[maximal disease\]). Large positive change in mTSS indicates disease progression; small positive/no change indicates slowing/halting of disease progression.
| units on a scale | DB Adalimumab | DB Placebo |
|---|---|---|
| Change From Baseline in Modified Total Sharp X-Ray Score at Week 26 | 1.5 ± 6.07 | 2.4 ± 3.20 |
Patients were ACR20 responders if they had: \>= 20% improvement in both tender joint count (68 joints) and in swollen joint count (66 joints) plus \>=20% improvement in at least 3 of the 5 remaining ACR core measures: patient's assessment of pain; patient's global assessment of disease activity; physician's global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant C-reactive protein. Patients who discontinued or switched to open-label adalimumab prior to Week 26 were considered non-responders.
| participants | DB Adalimumab | DB Placebo |
|---|---|---|
| Number of Participants Meeting ACR20 Response Criteria at Week 26 (ACR: American College of Rheumatology) | 129 | 92 |
Patients were ACR50 responders if they had: \>= 50% improvement in both tender joint count (68 joints) and in swollen joint count (66 joints) plus \>=50% improvement in at least 3 of the 5 remaining ACR core measures: patient's assessment of pain; patient's global assessment of disease activity; physician's global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant C-reactive protein. Patients who discontinued or switched to open-label adalimumab prior to Week 26 were considered non-responders.
| participants | DB Adalimumab | DB Placebo |
|---|---|---|
| Number of Participants Meeting ACR50 Response Criteria at Week 26 (ACR: American College of Rheumatology) | 110 | 63 |
Patients were ACR70 responders if they had: \>= 70% improvement in both tender joint count (68 joints) and in swollen joint count (66 joints) plus \>=70% improvement in at least 3 of the 5 remaining ACR core measures: patient's assessment of pain; patient's global assessment of disease activity; physician's global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant C-reactive protein. Patients who discontinued or switched to open-label adalimumab prior to Week 26 were considered non-responders.
| participants | DB Adalimumab | DB Placebo |
|---|---|---|
| Number of Participants Meeting ACR70 Response Criteria at Week 26 (ACR: American College of Rheumatology) | 81 | 37 |
Disease Activity Score (DAS28) is a combined index used to measure disease activity in patients with rheumatoid arthritis. Calculation of the DAS28 score used the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity, and the erythrocyte sedimentation rate. DAS28(ESR) scores range from 0 (no disease activity) to 9 (maximal disease activity); decrease is indicative of improvement in disease activity.
| units on a scale | DB Adalimumab | DB Placebo |
|---|---|---|
| Change From Baseline in Disease Activity Score (DAS28[ESR]) at Week 26 | -2.8 ± 1.63 | -1.8 ± 1.79 |
Disease Activity Score (DAS28) is a combined index used to measure disease activity in patients with rheumatoid arthritis. Calculation of the DAS28 score used the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity, and the erythrocyte sedimentation rate. DAS28(ESR) scores range from 0 (no disease activity) to 9 (maximal disease activity); decrease is indicative of improvement in disease activity. DAS28(ESR) score \<2.6 was defined as clinical remission of disease.
| participants | DB Adalimumab | DB Placebo |
|---|---|---|
| Number of Participants Achieving Clinical Remission, Defined by Disease Activity Score (DAS28[ESR]) <2.6, at Week 26 | 52 | 24 |
Adverse events were collected at designated study visits for all participants who were randomized and received at least 1 dose of study drug. The number of participants who experienced any adverse event (serious or non-serious) while receiving double-blind study drug is summarized. See the Reported Adverse Event section for details.
| participants | DB Adalimumab | DB Placebo |
|---|---|---|
| Number of Participants Who Reported Any Adverse Event (Serious or Non-serious) on Double-blind Study Drug Through Week 26 | 138 | 117 |
Modified Total Sharp Score (mTSS) is a measure of joint health, used in evaluation of inhibition of radiographic progression of disease. Digitized X-rays of hands and feet were obtained then scored in a blinded manner: for erosions (0 \[no damage\] to 5 \[complete collapse or total destruction of joint\]) and for joint space narrowing (0 \[no damage\] to 4 \[complete luxation of joint\]). Scores were added, giving total mTSS score (0 \[normal\] to 380 \[maximal disease\]). Large positive change in mTSS indicates diseae progression; small positive/no change indicates slowing/halting of disease progression.
| units on a scale | DB Adalimumab/OL Adalimumab | DB Placebo/OL Adalimumab | DB Adalimumab/RE OL Adalimumab | DB Placebo/RE OL Adalimumab |
|---|---|---|---|---|
| Change From Baseline in Modified Total Sharp X-Ray Score at Week 52 | 1.6 ± 6.50 | 2.1 ± 3.25 | 9.6 ± 11.76 | 6.8 ± 9.37 |
Patients were ACR20 responders if they had: \>=20% improvement in both tender joint count (68 joints) and in swollen joint count (66 joints) plus \>=20% improvement in at least 3 of the 5 remaining ACR core measures: patient's assessment of pain; patient's global assessment of disease activity; physician's global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire (HAQ); and acute phase reactant C-reactive protein.
| participants | DB Adalimumab/OL Adalimumab | DB Placebo/OL Adalimumab | DB Adalimumab/RE OL Adalimumab | DB Placebo/RE OL Adalimumab |
|---|---|---|---|---|
| Number of Participants Meeting ACR20 Response Criteria at Week 52 (ACR: American College of Rheumatology) | 129 | 113 | 4 | 21 |
Patients were ACR50 responders if they had: \>=50% improvement in both tender joint count (68 joints) and in swollen joint count (66 joints) plus \>=50% improvement in at least 3 of the 5 remaining ACR core measures: patient's assessment of pain; patient's global assessment of disease activity; physician's global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire (HAQ); and acute phase reactant C-reactive protein.
| participants | DB Adalimumab/OL Adalimumab | DB Placebo/OL Adalimumab | DB Adalimumab/RE OL Adalimumab | DB Placebo/RE OL Adalimumab |
|---|---|---|---|---|
| Number of Participants Meeting ACR50 Response Criteria at Week 52 (ACR: American College of Rheumatology) | 117 | 101 | 2 | 15 |
Patients were ACR70 responders if they had: \>=70% improvement in both tender joint count (68 joints) and in swollen joint count (66 joints) plus \>=70% improvement in at least 3 of the 5 remaining ACR core measures: patient's assessment of pain; patient's global assessment of disease activity; physician's global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire (HAQ); and acute phase reactant C-reactive protein.
| participants | DB Adalimumab/OL Adalimumab | DB Placebo/OL Adalimumab | DB Adalimumab/RE OL Adalimumab | DB Placebo/RE OL Adalimumab |
|---|---|---|---|---|
| Number of Participants Meeting ACR70 Response Criteria at Week 52 (ACR: American College of Rheumatology) | 87 | 85 | 0 | 10 |
Disease Activity Score (DAS28) is a combined index used to measure disease activity in patients with rheumatoid arthritis. Calculation of the DAS28 score used the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity, and the erythrocyte sedimentation rate. DAS28(ESR) scores range from 0 (no disease activity) to 9 (maximal disease activity); decrease is indicative of improvement in disease activity.
| units on a scale | DB Adalimumab/OL Adalimumab | DB Placebo/OL Adalimumab | DB Adalimumab/RE OL Adalimumab | DB Placebo/RE OL Adalimumab |
|---|---|---|---|---|
| Change From Baseline in Disease Activity Score (DAS28[ESR]) at Week 52 | -3.7 ± 1.14 | -3.7 ± 1.58 | -1.9 ± 1.22 | -3.4 ± 1.29 |
Disease Activity Score (DAS28) is a combined index used to measure disease activity in patients with rheumatoid arthritis. Calculation of the DAS28 score used the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity, and the erythrocyte sedimentation rate. DAS28(ESR) scores range from 0 (no disease activity) to 9 (maximal disease activity); decrease is indicative of improvement in disease activity. DAS28(ESR) score \<2.6 was defined as clinical remission of disease.
| participants | DB Adalimumab/OL Adalimumab | DB Placebo/OL Adalimumab | DB Adalimumab/RE OL Adalimumab | DB Placebo/RE OL Adalimumab |
|---|---|---|---|---|
| Number of Participants Achieving Clinical Remission, Defined by Disease Activity Score (DAS28[ESR]) <2.6, at Week 52 | 62 | 55 | 0 | 4 |
Adverse events were collected at designated study visits for all participants who were randomized and received at least 1 dose of adalimumab. The number of participants who experienced any adverse event (serious or non-serious) while receiving any adalimumab during the study (double-blind adalimumab and/or open-label) is summarized. See the Reported Adverse Event section for details.
| participants | Any Adalimumab |
|---|---|
| Number of Participants Who Reported Any Adverse Event (Serious or Non-serious) While Receiving Adalimumab Through Week 52 | 289 |
Collected over Through Week 26 for all participants who received at least 1 dose of blinded study drug (adalimumab or placebo) or through Week 52 for participants who received any adalimumab (double-blind and/or open-label, including rescue) in addition to methotrexate.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DB Adalimumab | — | 7/171 (4.1%) | 104/171 (60.8%) |
| DB Placebo | — | 4/163 (2.5%) | 83/163 (50.9%) |
| Any Adalimumab | — | 21/326 (6.4%) | 277/326 (85%) |
| Event | DB Adalimumab | DB Placebo | Any Adalimumab |
|---|---|---|---|
| PneumoniaInfections and infestations | 1/171 | 0/163 | 4/326 |
| Acute myocardial infarctionCardiac disorders | 0/171 | 1/163 | 0/326 |
| Pneumocystis jiroveci pneumoniaInfections and infestations | 0/171 | 1/163 | 0/326 |
| Back painMusculoskeletal and connective tissue disorders | 0/171 | 1/163 | 0/326 |
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 0/171 | 1/163 | 0/326 |
| Systemic lupus erythematosusMusculoskeletal and connective tissue disorders | 0/171 | 1/163 | 0/326 |
| Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders | 0/171 | 1/163 | 1/326 |
| CataractEye disorders | 0/171 | 0/163 | 2/326 |
| GastroenteritisInfections and infestations | 0/171 | 0/163 | 2/326 |
| Vertigo positionalEar and labyrinth disorders | 1/171 | 0/163 | 1/326 |
| Event | DB Adalimumab | DB Placebo | Any Adalimumab |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 26/171 | 27/163 | 97/326 |
| StomatitisGastrointestinal disorders | 6/171 | 15/163 | 17/326 |
| Injection site reactionGeneral disorders | 10/171 | 1/163 | 28/326 |
| Alanine aminotransferase increasedInvestigations | 13/171 | 6/163 | 28/326 |
| Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders | 6/171 | 4/163 | 28/326 |
| Hepatic function abnormalHepatobiliary disorders | 14/171 | 9/163 | 24/326 |
| RashSkin and subcutaneous tissue disorders | 10/171 | 5/163 | 26/326 |
| EczemaSkin and subcutaneous tissue disorders | 6/171 | 6/163 | 24/326 |
| Aspartate aminotransferase increasedInvestigations | 11/171 | 5/163 | 22/326 |
| DiarrhoeaGastrointestinal disorders | 5/171 | 1/163 | 18/326 |
| Age Continuous(years) | DB Adalimumab | DB Placebo | Total |
|---|---|---|---|
| Mean | 54.0 ± 13.13 | 54.0 ± 13.20 | 54.0 ± 13.15 |
| Sex: Female, Male(Participants) | DB Adalimumab | DB Placebo | Total |
|---|---|---|---|
| Female | 144 | 128 | 272 |
| Male | 27 | 35 | 62 |
| Region of Enrollment(participants) | DB Adalimumab | DB Placebo | Total |
|---|---|---|---|
| Japan | 171 | 163 | 334 |
The record gives a start of Mar 2009, a primary completion of Mar 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2012, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab